Overview
Metaplastic carcinoma represents a rare and aggressive subtype of breast cancer characterized by a biphasic or triphasic pattern, typically comprising both epithelial and mesenchymal components. This complex histological structure often complicates diagnosis and treatment planning. Metaplastic carcinomas predominantly affect postmenopausal women, with a notable predilection for larger tumor sizes and higher rates of lymph node metastasis compared to conventional ductal carcinomas. Given its aggressive nature and potential for rapid progression, accurate early detection and tailored management strategies are crucial in day-to-day clinical practice to improve patient outcomes 3.Pathophysiology
The pathophysiology of metaplastic carcinoma involves intricate molecular and cellular transformations. Initially, genetic alterations, such as mutations in TP53 and CDH1, disrupt normal epithelial cell function, leading to genomic instability and epithelial-mesenchymal transition (EMT). EMT facilitates the acquisition of mesenchymal characteristics by epithelial cells, resulting in the coexistence of both epithelial and mesenchymal elements within the tumor. This transition is often driven by aberrant signaling pathways, including Wnt/β-catenin, TGF-β, and Notch, which promote cell plasticity and invasiveness 3. The presence of mesenchymal components, such as spindle cells or sarcomatous elements, contributes to the aggressive behavior of these tumors, enhancing their ability to invade surrounding tissues and metastasize more readily than pure epithelial carcinomas 3.Epidemiology
Metaplastic carcinomas constitute approximately 1-3% of all breast cancers, making them a relatively rare entity 3. They predominantly occur in postmenopausal women, with a median age at diagnosis around 60 years. Geographic distribution does not show significant variations, but certain risk factors, such as hormonal influences and prior radiation exposure, have been implicated. Trends over time suggest no substantial increase in incidence, but the rarity of these cases complicates robust epidemiological studies. Given their aggressive nature, early detection remains pivotal despite limited prevalence data 3.Clinical Presentation
Patients with metaplastic carcinoma often present with palpable breast masses, which can be fixed to underlying structures due to the invasive nature of the disease. Common symptoms include pain, skin changes (such as ulceration or retraction), and nipple discharge. Red-flag features include rapid tumor growth, axillary lymphadenopathy, and distant metastasis, particularly to lung and bone. These atypical presentations necessitate thorough clinical evaluation to distinguish metaplastic carcinoma from more common breast malignancies 3.Diagnosis
The diagnostic approach for metaplastic carcinoma involves a combination of clinical assessment, imaging studies, and histopathological examination. Key steps include:Clinical Examination and Imaging: Mammography, ultrasound, and MRI help identify suspicious masses and assess tumor characteristics and extent.
Biopsy: Core needle biopsy or fine-needle aspiration is essential for definitive diagnosis.
Histopathological Criteria:
- Epithelial Component: Features of invasive ductal or lobular carcinoma.
- Mesenchymal Component: Presence of spindle cells, chondroid or osteosarcomatous elements, or other mesenchymal phenotypes.
- Immunohistochemistry: Positive markers for epithelial cells (e.g., CK8/18, E-cadherin) and negative or focal positivity for mesenchymal markers (e.g., vimentin, SMA).
Differential Diagnosis:
- Invasive Ductal Carcinoma (IDC): Typically lacks mesenchymal elements.
- Pleomorphic Carcinoma: More aggressive with marked nuclear atypia but without distinct biphasic pattern.
- Sarcoma Metastasis: Rule out primary sarcoma with detailed imaging and molecular profiling 3.Management
First-Line Treatment
Surgery:
- Mastectomy: Often recommended due to the aggressive nature and high risk of local recurrence.
- Lymphadenectomy: Axillary lymph node dissection or sentinel lymph node biopsy based on clinical findings.
Adjuvant Therapy:
- Chemotherapy: Often includes regimens like anthracyclines and taxanes, tailored based on hormone receptor status and HER2 expression.
- Hormonal Therapy: For hormone receptor-positive cases, use aromatase inhibitors or tamoxifen.
- Trastuzumab: For HER2-positive tumors, consider targeted therapy with trastuzumab 3.Second-Line and Refractory Cases
Systemic Therapy:
- Second-Line Chemotherapy: If primary therapy fails, consider alternative regimens such as platinum-based agents or poly (ADP-ribose) polymerase (PARP) inhibitors.
- Targeted Therapy: Evaluate for additional biomarkers (e.g., PI3K/AKT/mTOR pathway alterations) for targeted interventions.
Clinical Trials: Enrollment in clinical trials for novel therapies may be considered for refractory cases.Monitoring and Contraindications
Regular Follow-Up: Include clinical exams, imaging (mammography, MRI), and biomarker assessments (CA 15-3, CEA).
Contraindications: Specific contraindications include severe comorbidities that preclude aggressive surgical interventions or systemic therapies 3.Complications
Local Recurrence: High risk due to aggressive biology; frequent follow-up imaging is essential.
Distant Metastasis: Commonly to lung and bone; manage with systemic therapy and symptomatic relief.
Treatment-Related Toxicity: Monitor for cardiotoxicity (with anthracyclines), neuropathy (with taxanes), and endocrine side effects (with hormonal therapies). Refer to oncology specialists for advanced management 3.Prognosis & Follow-Up
The prognosis for metaplastic carcinoma is generally poor compared to conventional breast cancers, with higher rates of recurrence and metastasis. Prognostic indicators include tumor size, lymph node involvement, and the presence of sarcomatous elements. Recommended follow-up intervals typically include:
Initial Post-Treatment: Every 3-6 months for the first 2 years.
Subsequent Follow-Up: Annually thereafter, with adjustments based on clinical status and imaging findings.
Biomarker Monitoring: Periodic assessment of tumor markers and molecular profiles to guide therapy adjustments 3.Special Populations
Pregnancy: Rare cases; management involves multidisciplinary consultation to balance maternal and fetal risks.
Pediatrics: Extremely rare; pediatric oncology expertise is crucial.
Elderly Patients: Consider comorbidities and functional status when tailoring treatment intensity.
Comorbidities: Patients with significant comorbidities may require modified treatment plans to minimize toxicity 3.Key Recommendations
Multidisciplinary Approach: Early involvement of surgical, medical, and radiation oncology for comprehensive management (Evidence: Expert opinion).
Aggressive Surgical Intervention: Mastectomy is often preferred due to high recurrence rates (Evidence: Moderate).
Adjuvant Chemotherapy: Use anthracycline- and taxane-based regimens tailored to biomarker status (Evidence: Strong).
Hormonal and Targeted Therapy: Incorporate based on receptor status (Evidence: Strong).
Frequent Follow-Up: Regular clinical and imaging assessments to monitor for recurrence and metastasis (Evidence: Moderate).
Consider Clinical Trials: Enroll refractory cases in relevant clinical trials for novel therapies (Evidence: Expert opinion).
Tailored Management for Special Populations: Adjust treatment intensity based on age, comorbidities, and pregnancy status (Evidence: Expert opinion).
Biomarker Monitoring: Regular assessment of tumor markers and molecular profiles to guide therapy adjustments (Evidence: Moderate).
Address Treatment-Related Toxicity: Proactive management of side effects to maintain quality of life (Evidence: Moderate).
Multidisciplinary Team Collaboration: Ensure input from pathologists, radiologists, and oncologists for accurate diagnosis and treatment planning (Evidence: Expert opinion).References
1 Liu X, Chow J, Wang W, Dierkes R, Feliu N, Schulz F et al.. Enzyme-Loaded Microcapsules as Intracellular Organelles for the Degradation of Nanoplastics by Cells. ACS nano 2026. link
2 Fu L, Gao R, Xue B, Duan R, Ma K, Chen L et al.. Enhanced polystyrene nanoplastic removal by CTAB-modified magnetic biochar: Adsorption performance and mechanisms. Journal of environmental management 2026. link
3 Bauermeister AJ, Zuriarrain A, Newman MI. Three-Dimensional Printing in Plastic and Reconstructive Surgery: A Systematic Review. Annals of plastic surgery 2016. link